Bacterial Peritonitis Due to
A carbapenem-resistant Acinetobacter baumannii strain was isolated from the peritoneal fluid of a patient with complicated intra-abdominal infection and evaluated at the Multidrug-resistant Organism Repository and Surveillance Network by wholegenome sequencing and real-time PCR. The isolate was sequence type 25 and susceptible to colistin and minocycline, with low MICs of tigecycline. bla NDM-1 was located on a plasmid with >99% homology to pNDM-BJ02. The isolate carried numerous other antibiotic resistance genes, including the 16S methylase gene, armA.
C
arbapenem-resistant Gram-negative organisms are emerging pathogens that threaten global public health and seriously challenge infection control and therapy efforts (1) (2) (3) . Though still relatively uncommon, the carbapenemase encoded by bla NDM has quickly established itself as one of the most important (4). First described in 2009 (5), the gene has since been identified in nearly every continent and has been detected in species as diverse as Acinetobacter baumannii and Vibrio cholerae (6) (7) (8) . Furthermore, the gene has been associated with a diverse range of plasmids that often harbor multiple antibiotic resistance genes (9) .
In 2012, the Multidrug-resistant Organism Repository and Surveillance Network (MRSN) (10) received a request from a Ministry of Health hospital in Tegucigalpa, Honduras, for assistance in identifying the genetic mechanism associated with an extensively drug-resistant (XDR) isolate of A. baumannii. The isolate was recovered from a 76-year-old male patient admitted for ongoing dialysis in the setting of dysfunctional hemodialysis access. On the second day of admission, a peritoneal catheter was placed and the patient was prescribed empirical ciprofloxacin (250 mg) and a single dose of cephalothin (2 g). Two days later, the patient developed a fever (38.2°C) and experienced right lower abdominal pain. Peritoneal fluid cultures revealed moderate growth of Gram-negative bacilli. The patient was prescribed ceftriaxone (2 g/day) followed by intravenous ciprofloxacin (200 mg every 12 h) and intraperitoneal ceftazidime (250 mg). The organism was identified as A. baumannii with resistance to the fluoroquinolones and ␤-lactams, including carbapenems. Prompt clinical improvement followed removal of the peritoneal dialysis catheter and the initiation of tigecycline (50 mg every 12 h). He was discharged 17 days later and completed a 10-day course of therapy with tigecycline.
The isolate was forwarded to the MRSN and tested for carbapenemase genes by real-time PCR (11) . Identification and antibiotic susceptibility tests were performed on three automated systems: the Vitek 2 (bioMérieux, Inc., NC), the BD Phoenix (BD Diagnostics Systems, MD), and the Microscan Walk-Away (Siemens Healthcare Diagnostics Inc., IL). MICs of colistin, minocycline, polymyxin B, and tigecycline were determined by Etest; colistin susceptibility was also assayed using broth microdilution.
Whole genome sequencing was performed using an Ion Torrent Personal Genome Machine (PGM) with 200-bp chemistry.
The isolate (MRSN 12227) was identified as A. baumannii. It was resistant to amikacin, ampicillin-sulbactam, aztreonam, cefepime, cefotaxime, ceftazidime, ceftriaxone, ciprofloxacin, gentamicin, imipenem, levofloxacin, meropenem, tetracycline, tobramycin, and trimethoprim-sulfamethoxazole using CLSI breakpoints (12) . The isolate was susceptible to minocycline (MIC ϭ 3 g/ml) and to colistin by broth microdilution (MIC ϭ 0.25 g/ml) and Etest (MIC ϭ 0.125 g/ml). It had low MICs of tigecycline (1.5 g/ml) and polymyxin B (0.25 g/ml), which correlate with the successful treatment of the patient with tigecycline.
MRSN 12227 was assigned to sequence type 25 (ST25) (Pasteur scheme), an ST that has been sporadically identified in a number of countries, including The Netherlands, Turkey, Greece, Italy, Sweden, and Singapore, and is not associated with any clonal complex (13, 14) . Though sporadic, ST25 appears to be a stable clone and has been implicated in clinical infections since 1985 (14) .
Mean coverage depth for genome assembly was 129-fold. MRSN 12227 carried bla NDM-1 on a plasmid that shared Ͼ99% homology to pNDM-BJ02, a plasmid initially identified in a clinical isolate of Acinetobacter lwoffii in Beijing, China (15) . Interestingly, we also identified this plasmid in a clinical isolate of A. schindleri recovered from a surveillance groin swab of a U.S. service member wounded in Afghanistan (16) . This plasmid is unclassifiable by PCR-based replicon typing, has a novel plasmid backbone sequence, and carries genes that encode a type IV secretion system (T4SS) that facilitates horizontal transmission (15) . The composition of the genetic region surrounding bla NDM shares common elements with other plasmids carrying bla NDM in Enterobacteriaceae (17) , including the putative bleomycin resistance gene ble MDL , the N-(5=-phosphoribosyl)anthranilate isomerase gene trpF, and the insertion sequence ISAba125 (Fig. 1) . pNDM-BJ02 also carries a nonfunctional copy of aphA6, which normally encodes an aminoglycoside-modifying enzyme (AME) that confers resistance to amikacin. The same genetic architecture is apparent in the plasmid from MRSN 12227, with an upstream transposition event seemingly disrupting the promoter region of aphA6. However, unlike the A. lwoffii (15) and A. schindleri (16) isolates that also carried this plasmid, MRSN 12227 is resistant to amikacin. This discrepancy was resolved when further analysis of the MRSN 12227 genome using ResFinder (18) revealed a chromosomal copy of the 16S methylase gene, armA, which confers resistance to all aminoglycosides (19) ( Table 1) . pNDM-BJ02 has been reported to have a very high frequency of transfer (9.1 ϫ 10 Ϫ3 to 1.3 ϫ 10 Ϫ2 per donor cell) to Escherichia coli J53 Azi r (15) . Our experience with bla NDM -carrying strains of Acinetobacter provides further evidence for the promiscuity of this plasmid. In both instances in which the MRSN has encountered bla NDM -carrying strains of Acinetobacter, pNDM-BJ02 has been its vehicle of transmission.
MRSN 12227 also carries plasmid pCTXM360, which harbors the ␤-lactamase gene bla CTX-M-15 (20) , and has two additional chromosomal insertions carrying multiple antibiotic resistance genes (Table 1 and Fig. 1 ). The first of these carries six antibiotic resistance loci, including the aforementioned 16S methylase gene armA and the macrolide resistance genes mphE and msrE ( Table 1 and Fig. 1 ). This structure has been identified on plasmids associated with Klebsiella oxytoca and Citrobacter freundii (GenBank accession numbers CP003684.1 and JX182975.1, respectively) and on the chromosome of A. baumannii MDR-TJ and TYTH-1 (21, 22) . The second region also includes multiple antibiotic resistance genes, including the tetracycline efflux gene tetB, the streptomycin resistance genes strA and strB, and the dihydropteroate synthase gene sul2. This region most closely resembles the Acinetobacter resistance island AbaR1 (23), which is widely distributed in Acinetobacter baumannii strains. MRSN 12227 carries the chromosomally encoded bla OXA-51 -like gene bla OXA-64 but does not carry any acquired class D carbapenemase genes, indicating that carbapenemase resistance in this strain is probably due to bla NDM-1 . This is the first report of bla NDM from Honduras, and it follows the recent identification of this gene in a strain of Klebsiella pneumoniae in neighboring Guatemala (24) . The current epidemiological evidence from the hospital supports nosocomial transmission of MRSN 12227, but further investigations are ongoing. The modified Hodge test and the Carba NP tests were both negative for MRSN 12227, but this is not unexpected for Acinetobacter (25) . Finally, pNDM-BJ02 appears to be emerging as a common vehicle for the horizontal transmission of bla NDM , particularly in Acinetobacter species. In vitro evidence suggests that this plasmid is highly promiscuous, and further research is warranted to see if this plasmid is capable of being transmitted and stably maintained in other clinically important bacteria.
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